KVSMedtronics statement of cash flows for the fiscal year ended April 2020. Consolidated Statement of Income, 12 Months Ended ($ millions) 2020 EST. April 26, 2019 Net Sales $33,002 $30,557 Costs and expenses Cost of products sold 9,901 9,155 Research and development expense 2,508 2,330 Selling, general, and administrative expense 11,254 10,418 Amortization of intangible assets 1,914 1,764 Restructuring charges, net 149 198 Certain litigation charges 150 166 Other operating expense, net 258 258 Operating profit (loss) 6,868 6,268 Other nonoperating income, net (373) (373) Interest expense 1,444 1,444 Income (loss) before income taxes 5,797 5,197 Income tax provision 870 547 Net income (loss) 4,927 4,650 Net (income) loss attributable to noncontrolling interests (19) (19) Net income (loss) attributable to Medtronic $4,908 $4,631 Consolidated Balance Sheet ($ millions) 2020 EST. April 26, 2019 Current assets Cash and cash equivalents $7,140 $ 4,393 Investments 5,455 5,455 Accounts receivable, net 6,732 6,222 Inventories, net 4,059 3,753 Other current assets 2,310 2,144 Total current assets 25,696 21,967 Property, plant, and equipment, net 4,946 4,675 Goodwill 39,959 39,959 Other intangible assets, net 18,646 20,560 Tax assets 1,650 1,519 Other assets 1,089 1,014 Total assets $91,986 $89,694 Current liabilities Current debt obligations $2,058 $838 Accounts payable 2,112 1,953 Accrued compensation 2,376 2,189 Accrued income taxes 627 567 Other accrued expenses 3,168 2,925 Total current liabilities 10,341 8,472 Long-term debt 22,428 24,486 Accrued compensation and retirement benefits 1,651 1,651 Accrued income taxes 3,069 2,838 Deferred tax liabilities 1,386 1,278 Other liabilities 825 757 Total liabilities 39,700 39,482 Shareholders' equity Ordinary shares 0 Additional paid-in capital 26,532 26,532 Retained earnings 28,325 26,270 Accumulated other comprehensive loss (2,711) (2,711) Total shareholders' equity 52,146 50,091 Noncontrolling interests 140 121 Total equity 52,286 50,212 Total liabilities and shareholders' equity $91,986 $89,694 Additional information CAPEX/Net sales 3.7% Depreciation expense $950 Dividends $2,853 Round answers to the nearest whole number, if applicable. Use a negative signs with you answers to indicate a use of cash/decrease in cash. Medtronic plc Forecasted Statement of Cash Flows ($ millions) 2020 Est. Net income (before non-controlling interest) Add: Depreciation Add: Amortization Change in Accounts receivable Change in Inventories, net Change in Other current assets Change in Tax assets Change in Other assets Change in Accounts payable Change in Accrued compensation Change in Accrued income taxes Change in Other accrued expenses Change in Accrued income taxes Change in Deferred tax liabilities Change in Other liabilities Net cash from operating activities Capital expenditures Net cash from investing activities Dividends Change in current debt obligations Change in L-T Debt Net cash from financing activities Net change in cash Beginning cash Ending cash